查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2002902

胃肠道疾病治疗市场：2026年至2032年全球市场预测（按适应症、药物类别、给药途径、剂型、分销管道和最终用户划分）

Gastrointestinal Diseases Therapeutics Market by Indication, Drug Class, Route Of Administration, Dosage Form, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，胃肠道疾病治疗市场价值将达到 435.2 亿美元，到 2026 年将成长至 453 亿美元，到 2032 年将达到 577.1 亿美元，复合年增长率为 4.11%。

主要市场统计数据
基准年 2025 435.2亿美元
预计年份：2026年 453亿美元
预测年份 2032 577.1亿美元
复合年增长率 (%) 4.11%

本书以简洁明了的方式概述了正在重新定义胃肠道疾病治疗策略的临床、商业性和营运趋势。

目前胃肠道治疗正处于临床复杂性、技术创新以及支付方和监管机构不断变化的期望交汇点。生物製剂的进步、人们对微生物组日益增长的兴趣以及精准诊断的复兴正在重塑从酸相关疾病到发炎性肠道疾病等多种疾病的研发重点。同时，医疗保健系统要求提供更清晰的真实世界价值证据，这正在改变临床项目的规划方式和商业化策略的优先顺序。

前瞻性地整合科学、监管和商业性因素，推动胃肠道治疗药物的研发和交付发生根本性变革。

在科学突破、监管进步和医疗模式转变的推动下，消化器官系统治疗领域正经历一场变革。首先，生物製药平台和标靶免疫调节剂的成熟正促使研发重点转向精确的作用机制。尤其是在发炎性肠道疾病领域，抗整合素药物和白细胞介素抑制剂彻底改变了治疗流程。同时，人们对肠道微生物组的重新关注也推动了对基于微生物组的疗法和非常规干预措施的投资，这些疗法有望提供除传统小分子化合物和质子帮浦阻断剂之外的全新治疗方法。

对近期关税变化如何重塑消化器官系统治疗药物的供应链、生产决策和商业谈判进行策略评估。

美国将于2025年实施新的关税措施，这些措施正对全球消化器官系统药物的供应链、筹资策略和成本结构产生连锁反应。关税调整将影响活性药物成分的成本，尤其是那些从海外供应商采购的成分，这可能会增加依赖跨境生产或大规模进口原材料的製造商的价格压力。因此，各公司需要重新审视其筹资策略和合约条款，以确保在确保产品品质和供应连续性的同时，获利。

详细的細項分析突显了临床、製药和分销管道中的差异因素，这些因素决定了每个治疗领域的引入途径和商业化优先事项。

细分市场层面的洞察揭示了不同适应症、药物类别、给药途径、分销管道、剂型和终端用户之间存在的细微机会和限制因素。就适应症而言，酸相关疾病包括消化不良、胃食道逆流和消化性溃疡，每种疾病都有其独特的诊断和治疗模式。另一方面，感染性胃肠炎涵盖细菌性、感染疾病和病毒性胃肠炎，每种疾病对急性期管理和合理使用抗生素的影响各不相同。发炎性肠道疾病分为克隆氏症和溃疡性大肠炎，其治疗途径包括手术和生物製药。此外，大肠激躁症分为便秘型、腹泻型和混合型，每种类型都需要针对特定症状采取个别化治疗方案。

区域比较观点揭示了世界各地市场在监管、支付方和基础设施方面的差异，这些差异影响着市场的存取、采用和供应策略。

区域趋势反映了法律规范、医疗服务体系和患者族群特征的差异，对制定研发重点和打入市场策略至关重要。在美洲，完善的临床研究基础设施、成熟的支付体系和先进的专科医疗网络为创新生物製药和复杂治疗方法的推广应用提供了支持，但也带来了严格的证据要求和价格压力。因此，製造商必须优先考虑可靠的临床终点和卫生经济学证据，以确保其产品在这些市场获得处方药资格和报销。

整合企业策略和生态系统伙伴关係，揭示创新、製造和数位整合如何重塑该领域的竞争优势。

消化器官系统疗法领域的企业发展趋势反映了广泛的策略立场，涵盖了从创新驱动型生物技术公司到大规模製造商和专业合约服务供应商。创新公司专注于开发下一代生物製剂、标靶小分子化合物和基于微生物组的治疗方法，通常利用精准医疗方法和生物标记主导的临床试验来识别对治疗有反应的患者群体。这些公司经常与临床研究网络和学术机构建立策略伙伴关係，以加速概念验证(PoC) 研究并检验差异化的临床终点。

以营运为重点的建议，整合供应链韧性、证据一致性和交付创新，以增强消化器官系统治疗的临床和商业性成果。

行业领导者应采取一系列切实可行的措施，将科学进步转化为永续的商业性成果和更佳的患者照护。首先，他们应优先考虑供应商，并协商灵活的合约来降低关税和地缘政治风险。投资双源策略并加强与契约製造的关係，将有助于降低脆弱性，并确保临床和商业性供应的连续性。

采用透明的多来源调查方法，结合文献整合、专家参与和情境分析，以检验策略见解和建议。

本分析的调查方法整合了多种证据来源和迭代检验步骤，以确保其稳健性和有效性。首先，透过全面的二次检索，整合了同侪审查的临床文献、监管指南、专利申请和治疗指南，建立了关于治疗机制、临床终点和标准实践的基于事实的基准。这项基础性工作确定了关键的知识缺口，并明确了后续主要检索的优先顺序。

简明扼要的结论强调，需要采取区域导向的综合方法来应对策略挑战，并将创新转化为对患者的影响。

总之，消化器官系统治疗领域正受到多种因素的共同影响而重组，这些因素包括生物製剂和微生物组研究领域的科学创新、监管机构对真实世界证据的重视、支付方对价值期望的转变，以及供应链和政策变化带来的营运压力。应对这些变化需要製定一项涵盖早期临床试验设计、生产规划和市场准入谈判的综合策略。那些积极主动地将证据产生与支付方需求结合、实现供应链多元化并投资于给药方法创新的机构，将在改善患者疗效的同时，获得竞争优势。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：胃肠道疾病治疗药物市场：依适应症划分

  • 与酸相关的疾病
    • 消化不良
    • 胃食道逆流症
    • 消化性溃疡
  • 传染性肠胃炎
    • 细菌性肠胃炎
    • 寄生虫感染疾病
    • 病毒性肠胃炎
  • 发炎性肠道疾病
    • 克隆氏症
    • 溃疡性大肠炎
  • 大肠激躁症
    • 便秘型
    • 腹泻型
    • 混合型

第九章：胃肠道药物市场：依药物类别划分

  • 氨基水杨酸类药物
  • 抗生素
    • Ciprofloxacin
    • 甲硝唑
    • Rifaximin
  • 止泻
  • 解痉药
  • 生物製药
    • 整合素抑制剂
    • 抗肿瘤坏死因子製剂
    • 白细胞介素抑制剂
  • H2受体拮抗剂
  • 泻药
  • 质子帮浦阻断剂

第十章：胃肠道疾病治疗药物市场：依给药途径划分

  • 口服
  • 肠外
  • 外用

第十一章 以剂型分類的胃肠道疾病治疗药物市场

  • 注射液
  • 口服粉剂
  • 口服悬浮液
  • 片剂和胶囊

第十二章：胃肠道疾病治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：胃肠道疾病治疗市场：依最终使用者划分

  • 诊所
  • 家庭医疗保健
  • 医院

第十四章：胃肠道疾病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：胃肠道疾病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：胃肠道药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国胃肠道疾病治疗市场

第十八章：中国胃肠道药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ferring BV
  • Gilead Sciences, Inc.
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Organon & Co.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Viatris Inc.
Product Code: MRR-957C47F91DC1

The Gastrointestinal Diseases Therapeutics Market was valued at USD 43.52 billion in 2025 and is projected to grow to USD 45.30 billion in 2026, with a CAGR of 4.11%, reaching USD 57.71 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 43.52 billion
Estimated Year [2026] USD 45.30 billion
Forecast Year [2032] USD 57.71 billion
CAGR (%) 4.11%

An incisive introduction outlining evolving clinical, commercial, and operational dynamics that are redefining therapeutic strategies across gastrointestinal disease care

The gastrointestinal therapeutics landscape sits at the intersection of clinical complexity, technological innovation, and evolving payer and regulatory expectations. Advances in biologics, growing attention to the microbiome, and a resurgence in precision diagnostics have collectively reshaped development priorities for conditions ranging from acid-related disorders to inflammatory bowel disease. At the same time, healthcare systems are demanding clearer evidence of real-world value, which is changing how clinical programs are designed and how commercialization strategies are prioritized.

Against this backdrop, stakeholders must reconcile short-term operational challenges with long-term therapeutic opportunity. Supply chain resiliency, regulatory agility, and differentiated clinical endpoints are increasingly central to program viability. Moreover, patient-centric care models and digital health integrations are redefining adherence, monitoring, and outcome measurement for chronic gastrointestinal conditions. Consequently, decision-makers need an integrated view that links clinical innovation with commercial viability and practical deployment in hospitals, clinics, and home healthcare environments.

This executive summary distills core dynamics shaping therapeutic development, delivery, and market access across key indications and product classes. It highlights structural shifts in demand, regulatory and policy influences, and actionable imperatives for industry leaders. By synthesizing clinical trends with operational and commercial realities, the narrative aims to equip executives and investors with a focused perspective for prioritizing investment, structuring partnerships, and accelerating patient impact.

A forward-looking synthesis of scientific, regulatory, and commercial forces that are driving fundamental transformation across gastrointestinal therapeutics development and delivery

The landscape of gastrointestinal therapeutics is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing care models. First, the maturation of biologic platforms and targeted immunomodulators is redirecting R&D toward precise mechanisms of action, particularly for inflammatory bowel disease where anti-integrin agents and interleukin inhibitors have altered treatment algorithms. At the same time, renewed interest in the gut microbiome has catalyzed investment in microbiome therapeutics and nontraditional interventions, which promise new modalities beyond classic small molecules and proton pump inhibitors.

Concurrently, regulatory authorities are emphasizing adaptive pathways and real-world evidence, which is shaping study design and post-market commitments. This regulatory shift favors programs that integrate pragmatic endpoints, longitudinal patient monitoring, and health economics analyses early in development. Moreover, the distribution and delivery models are evolving; telehealth and remote patient monitoring are increasing the feasibility of home healthcare administration for selected therapies, while hospital-based specialty pharmacies continue to play a pivotal role for complex biologics.

Finally, commercial dynamics are shifting as payers insist on demonstrable value and cost-effectiveness. Manufacturers are responding with innovative pricing and evidence-generation strategies, including outcomes-based contracting and risk-sharing arrangements. Taken together, these shifts demand integrated strategies that span clinical development, regulatory engagement, supply chain planning, and payer dialogue in order to translate scientific advances into sustainable patient access and commercial success.

A strategic assessment of how recent tariff shifts reshape supply chains, manufacturing decisions, and commercial negotiations for gastrointestinal therapeutics

The introduction of new tariff measures in the United States in 2025 has implications that ripple across global supply chains, procurement strategies, and cost structures for gastrointestinal therapeutics. Tariff adjustments influence the cost of active pharmaceutical ingredients, particularly those sourced from international suppliers, and can increase the price pressure on manufacturers who rely on cross-border manufacturing and bulk raw material imports. Consequently, firms must reassess sourcing strategies and contract terms to preserve margins while maintaining product quality and continuity of supply.

In addition to direct cost implications, tariffs can accelerate strategic shifts in manufacturing geography and vertical integration. Companies may respond by nearshoring production of key intermediates, expanding domestic contract manufacturing capacity, or negotiating longer-term supplier agreements to dampen price volatility. These operational responses often require capital expenditure and longer lead times, and they can also affect timelines for clinical supply and commercial rollouts. Moreover, tariff-related cost increases may influence pricing negotiations with payers and hospital systems, prompting manufacturers to invest proactively in value demonstrations and real-world evidence to justify pricing decisions.

Policy uncertainty stemming from tariff regimes also impacts investor sentiment and M&A activity. Some investors may demand clearer visibility on supply chain risk mitigation before committing to sizeable transactions, while others may view tariffs as a catalyst for consolidation and strategic partnerships that secure localized manufacturing. Ultimately, companies that adopt a multifaceted response-combining supplier diversification, contractual protections, and transparent engagement with payers and purchasers-will be better positioned to manage the cumulative impacts while protecting patient access to essential gastrointestinal therapies.

Detailed segmentation analysis highlighting clinical, formulation, and channel differentiators that determine adoption pathways and commercialization priorities across therapeutic categories

Segment-level insights reveal nuanced opportunities and constraints across indications, drug classes, routes of administration, distribution channels, dosage forms, and end users. In indications, acid-related disorders encompass dyspepsia, gastroesophageal reflux disease, and peptic ulcer disease each with distinctive diagnostic and treatment patterns, while infectious gastroenteritis spans bacterial gastroenteritis, parasitic infections, and viral gastroenteritis that differ in acute management and antimicrobial stewardship implications. Inflammatory bowel disease bifurcates into Crohn's disease and ulcerative colitis with divergent surgical and biologic treatment pathways, and irritable bowel syndrome divides into constipation-predominant, diarrhea-predominant, and mixed type presentations that require personalized symptom-targeted approaches.

From a drug class perspective, traditional categories such as aminosalicylates, antibiotics, antidiarrheals, antispasmodics, H2 receptor antagonists, laxatives, and proton pump inhibitors continue to serve core therapeutic needs, while biologics and their subtypes-including anti-integrin agents, anti-tumor necrosis factor agents, and interleukin inhibitors-drive differentiated value in moderate-to-severe inflammatory conditions. Among antibiotics, agents like ciprofloxacin, metronidazole, and rifaximin play specific roles in treating distinct infectious etiologies, which underscores the importance of stewardship and resistance monitoring. Routes of administration, whether oral, parenteral, or topical, influence patient adherence, care setting requirements, and formulation innovation priorities.

Distribution channels such as hospital pharmacy, online pharmacy, and retail pharmacy each impose different commercial and regulatory dynamics that affect reimbursement, patient access, and adherence. Dosage form considerations-injectable solution, oral powder, oral suspension, and tablet capsule-shape manufacturing complexity, cold chain needs, and opportunities for delivery innovation. Finally, end-user segmentation including clinics, home healthcare, and hospitals frames adoption pathways and training requirements for new therapies. Taken together, these segmentation insights suggest that successful product strategies must be tailored across indication-specific clinical needs, differentiated molecule classes, pragmatic route and dosage considerations, and channel- and end-user-specific commercialization plans.

Comparative regional perspectives that illuminate regulatory, payer, and infrastructure variations shaping access, adoption, and supply strategies across global markets

Regional dynamics are pivotal in shaping development priorities and market access strategies, reflecting differences in regulatory frameworks, healthcare delivery systems, and patient demographics. In the Americas, strong clinical research infrastructure, established payer systems, and advanced specialty care networks support the uptake of innovative biologics and complex therapeutic regimens, while also presenting stringent evidence requirements and pricing pressures. As a result, manufacturers must prioritize robust clinical endpoints and health economics evidence to secure formulary placement and reimbursement in these markets.

In Europe, Middle East & Africa, regulatory diversity and varied reimbursement environments create both opportunities and challenges. Western European markets tend to demand comprehensive comparative effectiveness data and value-based narratives, while emerging markets in the region may prioritize affordability and supply chain reliability. Meanwhile, the Middle East and Africa present growth potential tied to expanding healthcare infrastructure and rising chronic disease burden, yet they require tailored access strategies and sensitivity to local procurement processes. Coordinated regional approaches that balance centralized evidence generation with localized commercialization tactics are therefore essential.

Across Asia-Pacific, rapid growth in healthcare investment, an expanding biologics manufacturing base, and evolving regulatory frameworks are key themes. Several markets in the region are enhancing local clinical trial capabilities and accelerating approvals for novel therapies, which can shorten time-to-market when regulatory strategies are well aligned. Nevertheless, price sensitivity and diverse reimbursement mechanisms necessitate flexible pricing and partnership models. In sum, regional strategies must account for distinct regulatory expectations, payer behaviors, and healthcare delivery infrastructures to convert scientific advances into accessible patient care.

A synthesis of corporate strategies and ecosystem partnerships that reveal how innovation, manufacturing, and digital integration are reshaping competitive advantage in the sector

Company-level dynamics in gastrointestinal therapeutics reflect a spectrum of strategic postures from innovation-focused biotechs to large-scale manufacturers and specialized contract service providers. Innovator organizations concentrate on advancing next-generation biologics, targeted small molecules, and microbiome-based interventions, often leveraging precision medicine approaches and biomarker-driven trials to delineate responder populations. These companies frequently pursue strategic partnerships with clinical research networks and academic centers to accelerate proof-of-concept studies and to validate differentiated clinical endpoints.

Meanwhile, established pharmaceutical manufacturers and generic producers are optimizing portfolios through life-cycle management, biosimilar development, and formulation enhancements that improve patient convenience and adherence. Contract manufacturing organizations and specialty CDMOs are expanding capacity to support both injectable biologics and complex oral formulations, which affects speed-to-market and cost structures for sponsors. Across the ecosystem, strategic alliances, licensing deals, and targeted acquisitions remain common mechanisms to complement internal capabilities and to fill pipeline gaps.

Finally, emerging companies and digital health entrants are integrating remote monitoring, patient-reported outcomes, and adherence technologies into product offerings, thereby enhancing real-world evidence collection and value demonstration. Collaboration between therapeutic developers and digital partners is strengthening post-market surveillance and payer negotiations. In aggregate, companies that blend scientific differentiation with operational excellence, payer-aligned evidence strategies, and agile commercialization models will be better positioned to succeed within this competitive landscape.

Operationally focused recommendations that integrate supply chain resilience, evidence alignment, and delivery innovation to strengthen clinical and commercial outcomes in gastrointestinal therapeutics

Industry leaders should adopt a set of pragmatic actions to convert scientific progress into durable commercial outcomes and improved patient care. First, prioritize supply chain resilience by diversifying suppliers of critical active pharmaceutical ingredients and negotiating flexible contracts to mitigate tariff-related and geopolitical risks. Investing in dual-source strategies and strengthening relationships with contract manufacturers will decrease vulnerability and preserve continuity of clinical and commercial supply.

Second, align clinical development with payer expectations through early engagement on endpoints, health economics, and real-world evidence generation. Implement adaptive trial designs and pragmatic studies that reflect clinical practice patterns; this will facilitate value conversations and support formulary negotiations. Third, accelerate delivery innovation by optimizing dosage forms and routes of administration that improve adherence and enable home-based care, while also exploring companion diagnostic strategies to target therapies to likely responders.

Fourth, pursue strategic collaborations that combine strengths across biologics development, microbiome science, and digital health to build differentiated evidence packages and patient support solutions. Fifth, adopt flexible commercialization models that tailor distribution strategies to local channel dynamics, balancing hospital pharmacy partnerships with retail and online pharmacy access where appropriate. Finally, enhance organizational capabilities in regulatory strategy, market access, and commercial analytics to ensure swift adaptation to policy shifts and evolving payer demands. Collectively, these steps will strengthen market positioning and improve patient outcomes.

A transparent, multi-source research methodology combining literature synthesis, expert engagement, and scenario analysis to validate strategic insights and recommendations

The research methodology underlying this analysis integrated multiple evidence streams and iterative validation steps to ensure robustness and relevance. Initially, comprehensive secondary research synthesized peer-reviewed clinical literature, regulatory guidance, patent filings, and treatment guidelines to establish a factual baseline for therapeutic mechanisms, clinical endpoints, and standard-of-care practices. This foundational work identified key knowledge gaps and informed subsequent primary research priorities.

Primary research included structured interviews with clinical experts, payer representatives, manufacturing specialists, and commercial leaders to capture contemporary practice patterns, pricing and reimbursement perspectives, and operational constraints. Insights from these interviews were triangulated with regulatory filings and published clinical trial results to validate assertions and to reconcile divergent viewpoints. In addition, scenario analyses were applied to assess supply chain contingencies and policy impacts, enabling exploration of plausible responses to tariff changes and manufacturing disruptions.

Quality assurance measures involved cross-validation of sources, peer review by subject-matter experts, and transparent documentation of assumptions and limitations. Ethical considerations included confidentiality protections for interview participants and adherence to data privacy standards. While every effort was made to ensure comprehensive coverage, users should interpret insights in the context of evolving clinical evidence and policy developments. The methodology thus combines rigorous literature synthesis, stakeholder engagement, and analytic modeling to produce actionable intelligence for decision-makers.

A concise conclusion that synthesizes strategic imperatives and reinforces the need for integrated, regionally aware approaches to convert innovation into patient impact

In conclusion, the gastrointestinal therapeutics landscape is being reshaped by converging forces: scientific innovation in biologics and microbiome research, regulatory emphasis on real-world evidence, evolving payer expectations for value, and operational pressures stemming from supply chain and policy changes. Navigating these shifts requires integrated strategies that span early clinical design, manufacturing planning, and market access negotiations. Organizations that proactively align evidence generation with payer needs, diversify supply chains, and invest in delivery innovation will secure competitive advantage while enhancing patient outcomes.

Moreover, regional nuances in regulatory and reimbursement environments mean that a one-size-fits-all approach is insufficient. Tailored regional strategies, agile manufacturing footprints, and collaborative partnerships will be critical to achieving both clinical impact and commercial sustainability. The cumulative effect of these actions is to create a more resilient and patient-centered therapeutic ecosystem that can respond to policy shifts and evolving clinical practice.

Stakeholders are therefore encouraged to convert these strategic imperatives into concrete initiatives-prioritizing projects that demonstrate clinical differentiation, operational robustness, and clear value to payers and providers. Doing so will accelerate the translation of scientific breakthroughs into accessible, effective therapies for patients living with gastrointestinal diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Diseases Therapeutics Market, by Indication

  • 8.1. Acid-Related Disorders
    • 8.1.1. Dyspepsia
    • 8.1.2. Gastroesophageal Reflux Disease
    • 8.1.3. Peptic Ulcer Disease
  • 8.2. Infectious Gastroenteritis
    • 8.2.1. Bacterial Gastroenteritis
    • 8.2.2. Parasitic Infections
    • 8.2.3. Viral Gastroenteritis
  • 8.3. Inflammatory Bowel Disease
    • 8.3.1. Crohn's Disease
    • 8.3.2. Ulcerative Colitis
  • 8.4. Irritable Bowel Syndrome
    • 8.4.1. Constipation-Predominant
    • 8.4.2. Diarrhea-Predominant
    • 8.4.3. Mixed Type

9. Gastrointestinal Diseases Therapeutics Market, by Drug Class

  • 9.1. Aminosalicylates
  • 9.2. Antibiotics
    • 9.2.1. Ciprofloxacin
    • 9.2.2. Metronidazole
    • 9.2.3. Rifaximin
  • 9.3. Antidiarrheals
  • 9.4. Antispasmodics
  • 9.5. Biologics
    • 9.5.1. Anti Integrin Agents
    • 9.5.2. Anti Tumor Necrosis Factor Agents
    • 9.5.3. Interleukin Inhibitors
  • 9.6. H2 Receptor Antagonists
  • 9.7. Laxatives
  • 9.8. Proton Pump Inhibitors

10. Gastrointestinal Diseases Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Gastrointestinal Diseases Therapeutics Market, by Dosage Form

  • 11.1. Injectable Solution
  • 11.2. Oral Powder
  • 11.3. Oral Suspension
  • 11.4. Tablet Capsule

12. Gastrointestinal Diseases Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Gastrointestinal Diseases Therapeutics Market, by End User

  • 13.1. Clinic
  • 13.2. Home Healthcare
  • 13.3. Hospital

14. Gastrointestinal Diseases Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Gastrointestinal Diseases Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gastrointestinal Diseases Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Gastrointestinal Diseases Therapeutics Market

18. China Gastrointestinal Diseases Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. AbbVie Inc.
  • 19.7. Amgen Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. Bausch Health Companies Inc.
  • 19.10. Bayer AG
  • 19.11. Biogen Inc.
  • 19.12. Boehringer Ingelheim International GmbH
  • 19.13. Bristol-Myers Squibb Company
  • 19.14. Cipla Limited
  • 19.15. Dr. Reddy's Laboratories Ltd.
  • 19.16. Eli Lilly and Company
  • 19.17. F. Hoffmann-La Roche Ltd
  • 19.18. Ferring B.V.
  • 19.19. Gilead Sciences, Inc.
  • 19.20. GSK plc
  • 19.21. Johnson & Johnson
  • 19.22. Merck & Co., Inc.
  • 19.23. Novartis AG
  • 19.24. Novo Nordisk A/S
  • 19.25. Organon & Co.
  • 19.26. Pfizer Inc.
  • 19.27. Sanofi S.A.
  • 19.28. Sun Pharmaceutical Industries Limited
  • 19.29. Takeda Pharmaceutical Company Limited
  • 19.30. Teva Pharmaceutical Industries Ltd.
  • 19.31. UCB SA
  • 19.32. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DYSPEPSIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PEPTIC ULCER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BACTERIAL GASTROENTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY VIRAL GASTROENTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CONSTIPATION-PREDOMINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DIARRHEA-PREDOMINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY MIXED TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY METRONIDAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RIFAXIMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIDIARRHEALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTISPASMODICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI INTEGRIN AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTI TUMOR NECROSIS FACTOR AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ACID-RELATED DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 262. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFECTIOUS GASTROENTERITIS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 265. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 267. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 268. GCC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC GASTROINTESTINAL DIS